| Purpose of the guideline: |
Lung cancer is the leading cause of the incidence and mortality of malignant tumors in China. The 5-year survival rate released in 2018 for China (2012-2015) was 19.7%, which is lower than the 5-year survival rates of Japan (33%) and South Korea (25%) in Asian countries from 2010 to 2014. Early diagnosis can significantly improve the 5-year overall survival rate and prognosis of lung cancer patients. But about 75% of patients in our country are diagnosed with advanced lung cancer missed the best opportunity for curative surgery. The early diagnosis and treatment of lung cancer are key to improving the prognosis of the disease. Therefore, experts from the Academic group of lung cancer in Chinese Thoracic Society and Chinese Alliance Against Lung Cancer Expert Group formulated the "Chinese Expert Consensus on the Diagnosis and Treatment of Lung Nodules" in 2015 to standardize the diagnosis and treatment of lung nodules. In 2018, this consensus was updated to formulate the "Chinese Expert Consensus on Diagnosis and Treatment of Lung Nodules (2018 edition)" , and widely applied in multiple Branch Centre of Chinese Alliance Against Lung Cancer, proposing the "Intelligent Treatment of Million Early Lung Cancer Project". On the basis of applied experience of the expert consensus in recent years, with reference to the latest evidence has been updated, “Chinese Expert Consensus on Diagnosis and Treatment of Lung Nodules (2023 version) ” was formulated. The updated content of this consensus mainly includes the following aspects: 1) defining the screening age of high-risk lung cancer populations in China based on the national conditions, and updating relevant lung cancer epidemiological data; 2) Propose definition of “difficult-to-determine pulmonary nodules” to avoid delaying the diagnosis and treatment; 3) Scientific evaluation of pulmonary nodules assisted by AI and proposing human-machine MDT to avoid the limitations of AI; 4) The evaluation of pulmonary nodules was divided into routine and individualized evaluations for different populations, and recommendations were made based on evidence-based management guidelines for different types and sizes of pulmonary nodules. In the updated Consensus, 27 consensus points were recommended to provide reference for clinicians in order to improve the prognosis of lung cancer in China. |
